Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines Lea S. FlockeRobert TrondlBernhard K. Keppler PRECLINICAL STUDIES Open access 18 March 2016 Pages: 261 - 268
Convection-enhancement delivery of liposomal formulation of oxaliplatin shows less toxicity than oxaliplatin yet maintains a similar median survival time in F98 glioma-bearing rat model Minghan ShiDavid FortinLéon Sanche PRECLINICAL STUDIES 09 March 2016 Pages: 269 - 276
Microtubule-stabilizing properties of the avocado-derived toxins (+)-(R)-persin and (+)-(R)-tetrahydropersin in cancer cells and activity of related synthetic analogs Jessica J. FieldArun KanakkantharaJohn H. Miller PRECLINICAL STUDIES 12 March 2016 Pages: 277 - 289
Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors Manisha H. ShahPaul LoriganPenella J. Woll PHASE I STUDIES Open access 09 March 2016 Pages: 290 - 299
Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison Anne-Charlotte DubbelmanCynthia M. NijenhuisJos H. Beijnen PHASE I STUDIES 28 March 2016 Pages: 300 - 318
A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers Andrew L. CovelerAndrew H. KoBrian Wolpin PHASE I STUDIES 18 March 2016 Pages: 319 - 328
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors B. Milojkovic KerklaanS. SlaterJ. H. M. Schellens PHASE I STUDIES 02 April 2016 Pages: 329 - 337
Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study Neeraj GuptaRichard LabotkaKarthik Venkatakrishnan PHASE I STUDIES Open access 02 April 2016 Pages: 338 - 346
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors Toshio ShimizuTakashi SetoKazuhiko Nakagawa PHASE I STUDIES Open access 22 March 2016 Pages: 347 - 354
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer Shivaani KummarJames L. WadeJames H. Doroshow PHASE II STUDIES 21 March 2016 Pages: 355 - 363
Effect of regulation reform on clinical trials for registering novel therapeutic agents in Taiwan: a chronological analysis I-Chen SunHorng-Shing ShyTzu-Ya Liao PHASE III STUDIES 16 January 2016 Pages: 364 - 370
RRx-001, A novel dinitroazetidine radiosensitizer Bryan OronskyJan ScicinskiSusan Knox REVIEW Open access 03 February 2016 Pages: 371 - 377
Targeted therapies in gastric cancer treatment: where we are and where we are going Gianluca TomaselloMichele GhidiniRodolfo Passalacqua REVIEW 12 February 2016 Pages: 378 - 393
Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget’s disease Satomi WatanabeMasayuki TakedaKazuhiko Nakagawa SHORT REPORT 09 February 2016 Pages: 394 - 396
A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib Linda MahjoubiAnas GazzahJean-Charles Soria SHORT REPORT 18 February 2016 Pages: 397 - 398